It seems Amarantus does not make a deal unless it is complicated like a Rube Goldberg machine. The good news is, they have a backer willing enough to give them $600k towards this reverse merger in order for ESS to be listed on NASDAQ. The next step is for MER to change its name to Cutanogen. Looking forward to news on Elto Pharma.